Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Toxicity of Glucantime. A case].

C Katlama, B Régnier, N Ben Salah

    Annales De Medecine Interne
    |January 1, 1985
    PubMed
    Summary

    N-methylglucamine antimoniate treats visceral leishmaniasis but can cause severe side effects. Careful dosage and regular monitoring of cardiac, liver, kidney, and blood parameters can prevent these serious complications.

    Related Concept Videos

    You might also read

    Related Articles

    Articles linked to this work by shared authors, journal, and citation graph.

    Sort by
    Same author

    Uptake of drug-reduced antiretroviral strategies and impact on costs over 2015-22: experience from an HIV clinic in Paris, France.

    The Journal of antimicrobial chemotherapy·2025
    Same author

    No virological failure in patients living with HIV with past NNRTI resistance-associated mutations switched to doravirine-containing regimens.

    The Journal of antimicrobial chemotherapy·2025
    Same author

    A case series of intermittent nucleoside analogue-based (NA) regimen to maintain HBV virological suppression in coinfected HBV/HIV patients with suppressed viremia.

    Infectious diseases now·2024
    Same author

    The burden of secrecy in the management of multimorbidity in older people living with HIV aged 70 and over.

    AIDS care·2024
    Same author

    Efficacy and safety of dolutegravir/lamivudine in virologically suppressed female participants: week 48 data from the pooled TANGO and SALSA studies.

    HIV medicine·2024
    Same author

    Comparison of HIV-Infected and Noninfected Patients Undergoing Bariatric Surgery: The ObeVIH Study.

    Journal of acquired immune deficiency syndromes (1999)·2022

    Area of Science:

    • Parasitology
    • Pharmacology
    • Clinical Medicine

    Background:

    • Visceral leishmaniasis is a severe parasitic disease.
    • N-methylglucamine antimoniate (Glucantime) is a primary treatment for visceral leishmaniasis.

    Observation:

    • N-methylglucamine antimoniate administration is associated with significant adverse events.
    • Complications include cardiac, hepatic, renal, and hematological toxicities.
    • These adverse effects can be life-threatening.

    Findings:

    • Adherence to the maximum recommended dosage of 6 cg/kg/day is crucial.
    • Regular clinical monitoring of pulse, blood pressure, and temperature is recommended.
    • Biological follow-up including serum creatinine, transaminases, and electrocardiography aids in early detection of toxicity.

    Implications:

    • Strict adherence to dosage guidelines and monitoring protocols can mitigate the risks associated with N-methylglucamine antimoniate.
    • This approach enhances patient safety during visceral leishmaniasis treatment.
    • Optimized treatment strategies are essential for managing leishmaniasis effectively and safely.

    Related Experiment Videos